Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate.
Dupont
A
A
D002191:Canrenoic Acid / Q000627:therapeutic use*; D006177:Gynecomastia / Q000139:chemically induced*; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D013148:Spironolactone / Q000009:adverse effects* / Q000627:therapeutic use
D011245:Pregnadienes; D013148:Spironolactone; D002191:Canrenoic Acid